Advertisement

Top Stories

May, 2019

Interim results from the ongoing ORION-3 study that examines the long-term safety and efficacy of small interfering RNA (siRNA) therapy drug inclisiran were shared today during the National Lipid Association’s (NLA) 2019 Scientific Sessions late-breaking abstract session.

Inclisiran, the first cholesterol-lowering therapy in the siRNA class, has the potential to deliver consistent lowering of LDL cholesterol through twice-a-year dosing.

Among the results presented today:

0
No votes yet
May, 2019

An encore presentation of the landmark cardiovascular outcomes trial REDUCE-IT™ (Reduction of Cardiovascular Events With EPA - Intervention Trial) was presented as a Late-Breaking Abstract by Amarin at the National Lipid Association 2019 Scientific Sessions, taking place in Miami May 16 – 19.

The presentation on Saturday, May 18, 4:40-4:50 p.m. included the total events analysis from the REDUCE-IT study, as first presented March 2019 and published in the Journal of the American College of Cardiology.

0
No votes yet
Apr, 2019

The NLA will be holding the following business meetings at the NLA Scientific Sessions in Miami, FL on May 16-19, 2019. Business meetings will take place on the general session stage and will include presentations of officer slates:

Northeast Lipid Association (NELA) Business Meeting

Friday, May 17, 2019 from 8:55 – 9:00 AM ET

 

Southwest Lipid Association (SWLA) Business Meeting

Friday, May 17, 2019 from 4:30 – 4:35 PM ET

 

Pacific Lipid Association (PLA) Business Meeting

0
No votes yet

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service